Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Design and methods for a Scandinavian pharmacovigilance study of osteonecrosis of the jaw and serious infections among cancer patients treated with antiresorptive agents for the prevention of skeletal-related events

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Positive Predictive Value of ICD-10 Diagnosis Codes for COVID-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A validated register-based algorithm to identify patients diagnosed with recurrence of malignant melanoma in denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Osteonekrose i relation til lavdosis knoglestyrkende behandling

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Workshop of European task force on medication-related osteonecrosis of the jaw-Current challenges

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Symptomer fra mundhulen

    Publikation: Bidrag til bog/antologi/rapportBidrag til kompendium/lecture notesUndervisningpeer review

  • John Acquavella
  • Vera Ehrenstein
  • Morten Schiødt
  • Uffe Heide-Jørgensen
  • Anders Kjellman
  • Svein Hansen
  • Cecilia Larsson Wexell
  • Bente Brokstad Herlofson
  • Sven Erik Noerholt
  • Haijun Ma
  • Katarina Öhrling
  • Rohini K Hernandez
  • Henrik Toft Sørensen
Vis graf over relationer

OBJECTIVE: Osteonecrosis of the jaw (ONJ) is a recognized complication of potent antiresorptive therapies, especially at the doses indicated to prevent skeletal complications for cancer patients with bone metastases. This paper describes the rationale and methods for a prospective, post-authorization safety study of cancer patients treated with antiresorptive therapies.

METHODS: As part of a comprehensive pharmacovigilance plan, developed with regulators' input, the study will estimate incidence of ONJ and of serious infections among adult cancer patients with bone metastases treated with denosumab (120 mg subcutaneously) or zoledronic acid (4 mg intravenously, adjusted for renal function). Patients will be identified using routinely collected data combined with medical chart review in Denmark, Sweden, and Norway. Followup will extend from the first administration of antiresorptive treatment to the earliest of death, loss-to-follow-up, or 5 years after therapy initiation. Results will be reported for three treatment cohorts: denosumab-naïve patients, zoledronic acid-naïve patients, and patients who switch from bisphosphonate treatment to denosumab. ONJ cases will be identified in three newly established national ONJ databases and adjudicated by the committee that functioned during the XGEVA(®) clinical trials program.

CONCLUSION: This study will provide a real world counterpart to the clinical trial-estimated risks for ONJ and serious infections for cancer patients initiating denosumab or zoledronic acid. The establishment of ONJ databases in the three Scandinavian countries will have potential benefits outside this study for the elucidation of ONJ risk factors and the evaluation of ONJ treatment strategies.

TidsskriftClinical Epidemiology
Sider (fra-til)267-72
Antal sider6
StatusUdgivet - 2016

ID: 49898083